Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 June 2025 | Story André Damons | Photo Department of Science, Technology, and Innovation
Prof Motlalepula Matsabisa
Prof Motlalepula Matsabisa, a specialist in indigenous knowledge systems from the Department of Pharmacology at the University of the Free State (UFS), and Jansie Niehaus, NSTF Executive Director and Company Director, at the Second Ministerial Belt and Road Science and Technology conference (BRT) in China.

Prof Motlalepula Matsabisa, a specialist in indigenous knowledge systems from the Department of Pharmacology at the University of the Free State (UFS), is part of a delegation with Prof Blade Nzimande, minister of Science, Technology, and Innovation (DSTI), to the Second Ministerial Belt and Road Science and Technology conference (BRT) in China. 

The conference is being held in Chengdu from 11-12 June 2025 and will gather representatives from state-level agencies, scientific academies, and innovation enterprises from countries involved in the Belt and Road Initiative, including members of the Association of Southeast Asian Nations (ASEAN) and the Shanghai Cooperation Organisation. The theme of the conference is “Together for Innovation, Development for All – Jointly Building a Scientific and Technological Innovation Community for the Belt and Road”. 

Prof Matsabisa, Research Director of the African Medicines Innovations and Technologies Development at the UFS, is the only person from a South African university to be invited by Prof Nzimande as part of this ministerial trip. Other members of the delegation include members from the minister’s department, CEOs and board members of agencies that report to the DSTI – namely Technology Innovation Agency (TIA), the National Science and Technology Forum (NSTF), Council for Scientific and Industrial Research (CSIR), National Advisory Council on Innovation, Human Sciences Research Council of South Africa, South African Council for Natural Scientific Professions, National Science and Technology Forum (NSTF), National Advisory Council on Innovation (NACI), South African National Space Agency and the National Research Foundation (NRF). 

As a guest professor at the Beijing University of Chinese Medicine (BUCM) in Beijing, Prof Matsabisa accompanied the delegation on a visit to the university where he has a longstanding relationship. The UFS has the only active university collaboration within the China-South African Science and Technology bilateral agreement.

 

Supporting around aspects of traditional medicine 

According to a statement on the South African government website, Prof Nzimande expressed the department’s intention to strengthen collaboration with the Beijing University and the Aerospace Research Institute of the Chinese Academy of Sciences, in the areas of indigenous knowledge systems and space science, respectively. The minister visited both the BUCM and the Aerospace Information Research Institute of the Chinese Academy of Sciences this week. 

“It is an honour to be part of the minister’s delegation given that I am the only person from a university amongst the agencies. The UFS is indeed very honoured to have been the only one identified to be in this ministerial trip. I am honoured to make connections with the decision-makers such as the chairperson of the board of TIA and the CEO of NSTF and all the other CEOs. It’s indeed an honour to share our work with people from NACI and the minister’s office at DSTI. This really could not have been a better opportune moment for me,” says Prof Matsabisa. 

According to him, he is there to support Prof Nzimande around aspects of traditional medicine as well as with his meeting with the Chinese Minister of Science and Technology during the signing of a letter of intent on traditional medicines including in the BRT conference where the minister will give a talk that will cover traditional medicines. Prof Matsabisa says he is looking forward to strengthening the relationships between the UFS and BUCM and China as well as sharing with the minister the joint projects and joint students from both institutions, hoping for continued support and funding.

“This trip has opened new opportunities. TIA has invited me and the UFS to be part of their new project on neurodegenerative diseases with Cuba. It was wonderful to hear that both the CEO and the chairperson of the board had already been briefed about me to be part of the project.

“It is also great to be present at the signing of the letter of intent on traditional medicine as it is important to know where the policies are heading.”

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept